AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25
ByAinvest
Friday, Aug 1, 2025 7:32 am ET1min read
Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25
Chardan Capital, a leading research firm, has maintained its "buy" rating on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), while raising its price target to $25.00, according to a recent report dated July 3rd, 2025 [1]. The firm's positive outlook on the company's prospects is driven by the strong clinical trial results and the potential of its 4D-150 treatment for diabetic macular edema (DME).The SPECTRA clinical trial, which evaluated 4D-150 in patients with DME, demonstrated significant clinical activity and durability over a 60-week period. The treatment showed sustained gains in visual acuity and anatomic control, with a clinically meaningful reduction in treatment burden compared to the standard of care, aflibercept 2mg Q8W [2][3]. These results have significantly boosted investor confidence in 4D Molecular Therapeutics' therapeutic potential.
Chardan Capital's positive assessment of 4D Molecular Therapeutics is supported by the company's strong pipeline of genetic medicine product candidates and its strategic focus on ophthalmology, cardiology, and pulmonology. The firm believes that the company's therapeutic vector evolution platform holds great promise for transforming treatment paradigms and providing unprecedented benefits to patients.
Despite the positive outlook, Chardan Capital acknowledges the challenges that 4D Molecular Therapeutics faces, including the competitive landscape and regulatory hurdles. However, the firm remains optimistic about the company's ability to navigate these challenges and achieve long-term success.
Reference List:
[1] https://www.marketbeat.com/instant-alerts/filing-decheng-capital-llc-sells-64485-shares-of-4d-molecular-therapeutics-inc-nasdaqfdmt-2025-07-30/
[2] https://www.ainvest.com/news/4d-molecular-therapeutics-shares-surge-50-89-positive-clinical-trial-results-2508/
[3] https://www.biospace.com/press-releases/4dmt-presents-positive-60-week-results-from-4d-150-spectra-clinical-trial-in-dme-and-regulatory-update
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet